LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: We are on time.

    Higuera Lucas, Juan / Soriano Cuesta, Cruz / López Olivencia, Marina / Blandino Ortíz, Aaron

    The Lancet regional health. Western Pacific

    2022  Volume 20, Page(s) 100411

    Language English
    Publishing date 2022-02-27
    Publishing country England
    Document type Journal Article
    ISSN 2666-6065
    ISSN (online) 2666-6065
    DOI 10.1016/j.lanwpc.2022.100411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: The right care at the right place with the right specialist.

    Higuera Lucas, Juan / Soriano Cuesta, Cruz / De Pablo, Raúl / Blandino Ortíz, Aaron

    The Lancet regional health. Western Pacific

    2021  Volume 14, Page(s) 100247

    Language English
    Publishing date 2021-08-20
    Publishing country England
    Document type Journal Article
    ISSN 2666-6065
    ISSN (online) 2666-6065
    DOI 10.1016/j.lanwpc.2021.100247
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Multicentre study of cefiderocol for treatment of Gram-negative bacteria infections in critically ill patients.

    Balandín, Bárbara / Pintado, Vicente / Pérez-Pedrero, María José / Martínez-Sagasti, Fernando / Sancho-González, Milagros / Soriano-Cuesta, Cruz / Gesso, Cristina Martín-Dal / Chicot, Marta / de Luna, Rafael Ruiz / Asensio-Martín, María José / Catalan, Mercedes / Díaz-Díaz, Juan José / Carbonell, Nieves / Iranzo, Reyes / Royuela, Ana / Ballesteros, Daniel

    International journal of antimicrobial agents

    2024  Volume 63, Issue 5, Page(s) 107121

    MeSH term(s) Humans ; Critical Illness ; Anti-Bacterial Agents/therapeutic use ; Cefiderocol ; Cephalosporins/therapeutic use ; Gram-Negative Bacterial Infections/drug therapy ; Gram-Negative Bacterial Infections/microbiology ; Male ; Middle Aged ; Aged ; Female ; Gram-Negative Bacteria/drug effects ; Treatment Outcome
    Chemical Substances Anti-Bacterial Agents ; Cefiderocol (SZ34OMG6E8) ; Cephalosporins
    Language English
    Publishing date 2024-02-24
    Publishing country Netherlands
    Document type Letter ; Multicenter Study
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2024.107121
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3368: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.

    Balandín, Bárbara / Ballesteros, Daniel / Pintado, Vicente / Soriano-Cuesta, Cruz / Cid-Tovar, Irene / Sancho-González, Milagros / Pérez-Pedrero, María José / Chicot, Marta / Asensio-Martín, María José / Silva, José Alberto / de Luna, Rafael Ruiz / Gesso, Cristina Martín-Dal / Rodríguez-Serrano, Diego Aníbal / Martínez-Sagasti, Fernando / Royuela, Ana

    International journal of antimicrobial agents

    2022  Volume 59, Issue 3, Page(s) 106536

    Abstract: This study aimed to assess the efficacy of ceftazidime/avibactam (C/A) in the treatment of infections due to Gram-negative bacteria (GNB) in critically ill patients. A multicentre, retrospective, observational study was conducted in critically ill ... ...

    Abstract This study aimed to assess the efficacy of ceftazidime/avibactam (C/A) in the treatment of infections due to Gram-negative bacteria (GNB) in critically ill patients. A multicentre, retrospective, observational study was conducted in critically ill patients receiving C/A for GNB infections. We evaluated demographic data, localisation and severity of infection, clinical and microbiological outcomes, and mortality. A total of 68 patients received C/A for serious GNB infections. The main infections were respiratory (33.8%), intra-abdominal (22.1%) and urinary tract infections (10.3%); bacteraemia was found in 22 cases (32.4%). Most infections were complicated by septic shock (58.8%) or sepsis (36.8%) and most of them required life-supporting therapies. Enterobacterales (79.4%) and Pseudomonas aeruginosa (19.1%) were the most frequently isolated bacteria; 84.2% of isolates were carbapenem-resistant. Thirty-four patients (50.0%) received C/A in combination with other antimicrobials. Fifty patients (73.5%) presented a favourable clinical response. Microbiological eradication was documented in 25 cases (36.8%). No significant differences were found in clinical response between patients treated with monotherapy or combined therapy (79.4% vs. 67.6%; P = 0.27). Overall intensive care unit (ICU) mortality was 41.2%. Univariate analysis showed that 30-day all-cause mortality was significantly (P < 0.05) associated with bacteraemia, previous corticosteroid use and the need of life-supporting therapies. C/A appears to be an effective therapy for severe infections due to GNB, including carbapenem-resistant isolates, in critically ill patients. C/A combination therapy was not associated with a higher clinical response. Mortality correlated significantly with the presence of bacteraemia, previous corticosteroid use and the need for life-supporting therapies.
    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/therapeutic use ; Ceftazidime/therapeutic use ; Critical Illness ; Drug Combinations ; Drug Resistance, Multiple, Bacterial ; Gram-Negative Bacteria ; Gram-Negative Bacterial Infections/drug therapy ; Gram-Negative Bacterial Infections/microbiology ; Humans ; Microbial Sensitivity Tests ; Retrospective Studies
    Chemical Substances Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; avibactam (7352665165) ; Ceftazidime (9M416Z9QNR)
    Language English
    Publishing date 2022-01-25
    Publishing country Netherlands
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2022.106536
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3368: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients

    Balandín, Bárbara / Ballesteros, Daniel / Pintado, Vicente / Soriano-Cuesta, Cruz / Cid-Tovar, Irene / Sancho-González, Milagros / Pérez-Pedrero, María José / Chicot, Marta / Asensio-Martín, María José / Silva, José Alberto / de Luna, Rafael Ruiz / Gesso, Cristina Martín-Dal / Rodríguez-Serrano, Diego Aníbal / Martínez-Sagasti, Fernando / Royuela, Ana

    International journal of antimicrobial agents. 2022 Mar., v. 59, no. 3

    2022  

    Abstract: This study aimed to assess the efficacy of ceftazidime/avibactam (C/A) in the treatment of infections due to Gram-negative bacteria (GNB) in critically ill patients. A multicentre, retrospective, observational study was conducted in critically ill ... ...

    Abstract This study aimed to assess the efficacy of ceftazidime/avibactam (C/A) in the treatment of infections due to Gram-negative bacteria (GNB) in critically ill patients. A multicentre, retrospective, observational study was conducted in critically ill patients receiving C/A for GNB infections. We evaluated demographic data, localisation and severity of infection, clinical and microbiological outcomes, and mortality. A total of 68 patients received C/A for serious GNB infections. The main infections were respiratory (33.8%), intra-abdominal (22.1%) and urinary tract infections (10.3%); bacteraemia was found in 22 cases (32.4%). Most infections were complicated by septic shock (58.8%) or sepsis (36.8%) and most of them required life-supporting therapies. Enterobacterales (79.4%) and Pseudomonas aeruginosa (19.1%) were the most frequently isolated bacteria; 84.2% of isolates were carbapenem-resistant. Thirty-four patients (50.0%) received C/A in combination with other antimicrobials. Fifty patients (73.5%) presented a favourable clinical response. Microbiological eradication was documented in 25 cases (36.8%). No significant differences were found in clinical response between patients treated with monotherapy or combined therapy (79.4% vs. 67.6%; P = 0.27). Overall intensive care unit (ICU) mortality was 41.2%. Univariate analysis showed that 30-day all-cause mortality was significantly (P < 0.05) associated with bacteraemia, previous corticosteroid use and the need of life-supporting therapies. C/A appears to be an effective therapy for severe infections due to GNB, including carbapenem-resistant isolates, in critically ill patients. C/A combination therapy was not associated with a higher clinical response. Mortality correlated significantly with the presence of bacteraemia, previous corticosteroid use and the need for life-supporting therapies.
    Keywords Pseudomonas aeruginosa ; adrenal cortex hormones ; bacteremia ; ceftazidime ; mortality ; observational studies ; septic shock ; therapeutics ; urinary tract
    Language English
    Dates of publication 2022-03
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2022.106536
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3368: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.

    Balandin, Bárbara / Ballesteros, Daniel / Ruiz de Luna, Rafael / López-Vergara, Loreto / Pintado, Vicente / Sancho-González, Milagros / Soriano-Cuesta, Cruz / Pérez-Pedrero, Maria José / Asensio-Martín, Maria José / Fernández-Simón, Inamculada / Rodríguez-Serrano, Diego / Silva, Alberto / Chicot, Marta / Iranzo, Reyes / Martínez-Sagasti, Fernando / Royuela, Ana

    International journal of antimicrobial agents

    2021  Volume 57, Issue 3, Page(s) 106270

    Abstract: Background: This study aimed to assess the efficacy of ceftolozane-tazobactam (C/T) for treating infections due to Pseudomonas aeruginosa (P. aeruginosa) in critically ill patients.: Patients and methods: A multicenter, retrospective and ... ...

    Abstract Background: This study aimed to assess the efficacy of ceftolozane-tazobactam (C/T) for treating infections due to Pseudomonas aeruginosa (P. aeruginosa) in critically ill patients.
    Patients and methods: A multicenter, retrospective and observational study was conducted in critically ill patients receiving different C/T dosages and antibiotic combinations for P. aeruginosa infections. Demographic data, localisation and severity of infection, clinical and microbiological outcome, and mortality were evaluated.
    Results: Ninety-five patients received C/T for P. aeruginosa serious infections. The main infections were nosocomial pneumonia (56.2%), intra-abdominal infection (10.5%), tracheobronchitis (8.4%), and urinary tract infection (6.3%). Most infections were complicated with sepsis (49.5%) or septic shock (45.3%), and bacteraemia (10.5%). Forty-six episodes were treated with high-dose C/T (3 g every 8 hours) and 38 episodes were treated with standard dosage (1.5 g every 8 hours). Almost half (44.2%) of the patients were treated with C/T monotherapy, and the remaining group received combination therapy with other antibiotics. Sixty-eight (71.6%) patients presented a favourable clinical response. Microbiological eradication was documented in 42.1% (40/95) of the episodes. The global ICU mortality was 36.5%. Univariate analysis showed that 30-day mortality was significantly associated (P < 0.05) with Charlson Index at ICU admission and the need of life-supporting therapies.
    Conclusions: C/T appeared to be an effective therapy for severe infections due to P. aeruginosa in critically ill patients. Mortality was mainly related to the severity of the infection. No benefit was observed with high-dose C/T or combination therapy with other antibiotics.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/therapeutic use ; Cephalosporins/therapeutic use ; Critical Illness ; Cross Infection/drug therapy ; Cross Infection/mortality ; Dose-Response Relationship, Drug ; Drug Resistance, Multiple, Bacterial ; Female ; Humans ; Intensive Care Units ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Pseudomonas Infections/drug therapy ; Pseudomonas Infections/mortality ; Pseudomonas aeruginosa/drug effects ; Pseudomonas aeruginosa/isolation & purification ; Retrospective Studies ; Spain ; Tazobactam/therapeutic use ; Treatment Outcome
    Chemical Substances Anti-Bacterial Agents ; Cephalosporins ; ceftolozane, tazobactam drug combination ; Tazobactam (SE10G96M8W)
    Language English
    Publishing date 2021-01-19
    Publishing country Netherlands
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2020.106270
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3368: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top